96results about "Phosphorus-oxygen lyases" patented technology

The methods and apparatus of the present invention allow the evaluation of inflammation of the esophagus. Measurements may be utilized, for example, to diagnose a disease of the esophagus, to monitor inflammation of the esophagus, or to access the treatment of a disease of the esophagus. In one embodiment, the invention comprises a method for measuring esophageal inflammation comprising deploying a device into the esophagus of a subject, removing the device after a predetermined period of time, analyzing the device for a diagnostic indicator of esophageal inflammation and evaluating the diagnostic indicator to diagnose esophageal inflammation.

The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.

In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided. In certain embodiments, provided herein are methods for hydration of non hydratable phospholipids (NHPs) within a lipid matrix. The methods enable migration of NHPs to an oil-water interface thereby allowing the NHPs to be reacted and / or removed from the lipids. In certain embodiments, provided is a method for removing NHPs, hydratable phospholipids, and lecithins from vegetable oils to produce a degummed oil or fat product that can be used for food production and / or non-food applications. In certain embodiments, provided herein are methods for hydration of NHPs followed by enzymatic treatment and removal of various phospholipids and lecithins. The methods provided herein can be practiced on either crude or water-degummed oils.

The invention discloses a crosslinking enzyme polymer based on polyamine-polyphenol codeposition, and a preparation method and application thereof, and belongs to the technical field of immobilized enzyme application. Graphene oxide is dispersed in a buffer solution, and then, polyphenol solution and multi-amido polymer solution are added into the buffer solution so as to react to obtain the polyamine-polyphenol modified graphene oxide. The polyamine-polyphenol modified graphene oxide carrier obtained by the method is used for the immobilized enzyme so as to obtain the crosslinking enzyme polymer. The polyamine-polyphenol modified graphene oxide carrier has the advantages of universality, high activity, simpleness in operation and the like.

The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

The invention provides a method for producing a terpene or a precursor thereof by microbial fermentation. Typically, the method involves culturing a recombinant bacterium in the presence of a gaseous substrate whereby the bacterium produces a terpene or a precursor thereof, such as mevalonic acid, isopentenyl pyrophosphate, dimethylallyl pyrophosphate, isoprene, geranyl pyrophosphate, farnesyl pyrophosphate, and / or farnesene. The bacterium may comprise one or more exogenous enzymes, such as enzymes in mevalonate, DXS, or terpene biosynthesis pathways.

The present invention is directed to enzymes having Asx-specific ligase and cyclase activity and to nucleic acids encoding those as well as methods of the manufacture of said enzymes. Further encompassed are methods and uses of these enzymes.

Disclosed is a polypeptide that recognizes immune cells, the polypeptide comprising the following amino acid sequence: (a) an amino acid sequence containing C terminal fragment sequence EQPDPGAVAAAAILRAILE of human Triokinase / FMN cyclase and the homologous sequence thereof; or (b) an amino acid sequence in which the amino acid sequence is substantially the same as described in (a), the substantially the same referred to amino acid sequence having at least 80% sequence identity to the amino acid sequence as described above in (a). Also disclosed in the present invention are a nucleotide sequence encoding the polypeptide; a polypeptide probe that targets recognized immune cells, comprises the polypeptide as described above and has a reporter group; a kit comprising the above-mentioned probe;and the use of the polypeptide or probe as described above in the preparation of the kit for mammalian living cell imaging.

The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

The invention is directed to a method for the production of a pertussis vaccine and, in particular, a detoxified pertussis vaccine comprising detoxified pertussis toxin (PT), detoxified pertussis lipopolysaccharide (P-LPS), and detoxified pertussis adenylate cyclase toxin (P-ACT). The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a detoxified vaccine to patients.

The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.